君實生物(01877.HK)澄清媒體報道
君實生物(01877.HK)公布,關注到有關自媒體公眾號撰寫的文章對涉及公司歷史沿革、對外合作、在研核心產品特瑞普利單抗注射液(商品名:拓益,項目代號:JS001)及重組全人源抗SARS-CoV-2單克隆抗體注射液(項目代號:JS016)的安全性數據及研發進展情況等內容進行報道,該內容全面失實,與客觀事實嚴重不符、相悖。
截至目前,JS016已順利完成中國、美國2項健康受試者I期研究。在國內,由公司發起的一項在新冠病毒感染者中評價JS016初步臨床療效和安全性的國際多中心Ib/II臨床研究仍按原計劃進行。JS016同時正在美國開展1項由禮來製藥發起的聯合LY-CoV555的II期研究等。
公司指,對於杜撰及傳播不實報道的機構、媒體和個人,將保留通過法律手段追責的權利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.